Empowering Clinicians: NeuroClues Raises $10M in Series A Funding to Revolutionize Neurological Disorder Diagnosis

We are thrilled to announce that neuroClues has successfully raised $10 million in our latest funding round, marking a significant milestone in our mission to transform the landscape of neurological disorder detection. As we face a future where one in three people will be affected by conditions like Parkinson's Disease and Alzheimer's Disease, the urgency of our work has never been greater. Our revolutionary approach aims to empower clinicians with advanced biomarkers that enable the identification of these disorders years before symptoms manifest, fundamentally changing patient care and intervention strategies. With this funding, we will be accelerating the development of our innovative diagnostic tools, which we aspire to position as the brain's stethoscope. Headquartered in Louvain-la-Neuve, Belgium, and with operational bases in Paris and New York, our passionate team of MedTech entrepreneurs and medical professionals is committed to bridging the gap between technology and healthcare. We are eager to connect with like-minded individuals, companies, and key opinion leaders who share our vision of advancing neurological care. This funding will not only enhance our research capabilities but also bolster our efforts to bring neuroClues' pioneering solutions to the EU and US markets. Together, we can change the trajectory of neurological healthcare—not just for the patients of today, but for future generations who will benefit from early detection and intervention. Thank you for joining us on this journey towards a healthier future.